Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by Spartrapon Oct 13, 2020 6:28pm

158 Views

Post# 31711471

RE:RE:RE:Theratechnologies Confirms Issuance Of U.S. Patent Covering

Great news indeed.. Unfortunately the patent alone won't protect TH from "skinny labeling" practices by generic drug makers, which will likely end up eating a significant part of the market opportunity, but it's giving a lot more credence to the whole NAFLD/NASH project. Hopefully, the F8 formula will be so much easier that patients will ask for "dispense as written" mentions on the script.